IL-6 is one of the main chemokines present in serum samples of cancer patients and elevated IL-6 levels have been shown to be an independent predictor of tumor recurrence, poor survival and tumor metastasis in a number of malignancies including breast, prostate and head and neck cancers [6–10]. This evidence concerns the gene IL6 and head and neck cancer.